Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson

Last Updated: January 22, 2020

DrugPatentWatch Database Preview

Patent: 9,228,018

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 9,228,018
Title:Antibody polypeptides that antagonize CD40L
Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single V.sub.H or V.sub.K domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
Inventor(s): Nadler; Steven G. (Princeton, NJ), Tamura; James K. (Yardley, PA), Price; Laura (Langhorne, PA), Rehfuss; Robert P. (North Wales, PA), Suchard; Suzanne J. (Wilmington, DE), Suri; Anish (Yardley, PA), Bryson; James William (Langhorne, PA), Yamniuk; Aaron (Lawrenceville, NJ), Grant; Steven (Swaffham Prior, GB), Ignatovich; Olga (Cambridge, GB), Drew; Philip (Histon, GB)
Assignee: BRISTOL-MYERS SQUIBB COMPANY (Princeton, NJ) DOMANTIS LIMITED (Brentford, Middlesex, GB)
Application Number:14/510,474
Patent Claims:see list of patent claims

Details for Patent 9,228,018

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Bristol Myers Squibb NULOJIX belatacept INJECTABLE; INJECTION 125288 001 2011-06-15   Start Trial BRISTOL-MYERS SQUIBB COMPANY (Princeton, NJ) DOMANTIS LIMITED (Brentford, Middlesex, GB) 2031-10-13 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.